In the one completed outcomes trial to date – the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial – in aortic stenosis patients, ezetimibe plus statin therapy did not reduce the ...
In the one completed outcomes trial to date – the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial – in aortic stenosis patients, ezetimibe plus statin therapy did not reduce the ...
FH is a genetic condition of very high cholesterol levels that presents a high risk for coronary artery disease.
FH is a genetic condition of very high cholesterol levels that presents a high risk for coronary artery disease.
Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...
I am a 69-year-old woman who was diagnosed with familial hypercholesterolemia (FH). I used statins for over a decade but developed vulvar lichen sclerosus (LS), which only went away when I stopped the ...
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of ...
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of ...
non-intensive statin) analysis. Results: The data of 179 patients receiving statins and/or ezetimibe, 50 of which with evolucumab and 129 without, were analyzed. Evolocumab add-on therapy over six ...
JMP Securities reissued their market outperform rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. They ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback